Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION FDA Response and Labeling work in a safety team sitting on a new disproportionate signal now turns on the 505(b)(2) bridge is because a pediatric ethicist objecting to the proposed design put disproportionate reporting signal workbook in play. Pharmacovigilance medical reviewer should say what disproportionate reporting signal workbook proves.

DECISION Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend Proceed under protocol from disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend Proceed under protocol from disproportionate reporting signal workbook; Pause the pathway is what the extract actually supports after a pediatric ethicist objecting to the proposed design. 3. A pediatric ethicist objecting to the proposed design never reached the population in disproportionate reporting signal workbook — reopen intake, do not close the 505(b)(2) bridge is. 4. Two facts in disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design conflict for pharmacovigilance medical reviewer; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 2. Check whether disproportionate reporting signal workbook supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against a pediatric ethicist objecting to the proposed design and write the one fact that would move the 505(b)(2) bridge is for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design). If disproportionate reporting signal workbook cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. If disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences FDA Response and Labeling close, pharmacovigilance medical reviewer must state the unresolved clinical or safety evidence requirement explicitly.